Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Oct-4 expression maintained stem cell properties in prostate cancer-derived CD133+MDR1+ cells

Satyanarayana Rentala^1,2, Lakshmi Narasu Mangamoori¹

¹Centre for Biotechnology, Institute of Science and Technology, Jawaharlal Nehru Technological University, Hyderabad; ²Department of Biotechnology, Chaitanya Bharathi Institute of Technology, Hyderabad, India.

For correspondence:- Lakshmi Mangamoori Email: narasu.lakshmi@yahoo.com

Received: 7 August 2008 Accepted: 15 October 2008 Published: 23 February 2009

Citation: Rentala S, Mangamoori LN. Oct-4 expression maintained stem cell properties in prostate cancer-derived CD133+MDR1+ cells. Trop J Pharm Res 2009; 8(1):3-9 doi: 10.4314/tjpr.v8i1.2

© 2009 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: CD133 (prominin-1), a 5-transmembrane glycoprotein, has recently been considered an important marker that represents the subset population of cancer stem-like cells. The purpose of the present study is to isolate cancerous stem-like cells from normal healthy volunteers and prostate cancer patients (CD133⁺) which also express MDR1 and to ascertain the influence of Oct-4 on ‘stem-ness’ and differentiation of these CD133⁺ cells towards epithelium.

Methods: CD133⁺ cells were isolated using magnetic beads from normal healthy volunteers and prostate cancer patients (NV-CD133⁺and PC-CD133⁺). The isolated cells were analyzed using flow cytometry and Western blot technique for CD133, MDR1 and Oct-4. CD133⁺MDR1⁺ cells were cultured in presence and absence of antihuman Oct-4 blocking antibody.

Results: PC-CD133⁺ cells displayed higher Oct-4 expression with the ability to self-renew and may represent a reservoir with differentiation potential for generating prostate cancer cells. Furthermore, PC-CD133⁺ cells highly co-expressed the multiple drug-resistant marker MDR1. The treatment with Oct-4 blocking antibody can specifically block the capability of PC-CD133⁺ cells to differentiate into prostate epithelial cells bearing CD57.

Conclusion: PC-CD133⁺ cells displayed a higher Oct-4 expression with the ability to self-renew and may represent a reservoir with differentiation potentials for progression of prostate cancer. The MDR1 expression of PC-CD133⁺ cells in vitro and in vivo is partially due to preferential activation of Oct-4 gene expression.

Keywords: Prostate cancer, Cancer stem-like cells, Oct-4, CD133, Multi-drug resistance1 (MDR1)